History of Kyowa KirinLearn more about our heritage and
contributions to healthcare

Kyowa Kirin is a pharmaceutical company,
formed from a combination of the depth of
experience
and strong business record of
Kyowa Hakko Kogyo and Kirin Pharma.

Find out the combined histories of Kyowa
Hakko Kogyo and Kirin Pharma, followed by the history
of Kyowa Kirin,
touching upon their
performance in the field of research and
development to date.

Chronology

1907

Establishment of Kirin Brewery Co., Ltd.

Kirin Brewery Co., Ltd.

1949

Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.

Kyowa Hakko Kogyo Co., Ltd.

1951

Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).

Lapping bus for commerce of Streptomycin

1956

Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C.

Invention of the process of L-glutamic acid production by fermentation (a world first).

1963

Initiation of full-scale involvement in the pharmaceutical business.

Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.

1967

Release of 5-FU, an anticancer drug.

1971

Release of Leunase, an anticancer drug.

1982

The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.

1988

Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).

La Jolla Institute

1990

elease of ESPO®, an erythropoietin (EPO) drug.

1991

Release of GRAN®, G-CSF drug.

Release of Coniel, a remedy for hypertension and agina pectoris.

2003

Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.

2007

The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug.

Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary.

Capital alliance between Kyowa Hakko Group and Kirin Group.

2008

Release of REGPARA®, a drug for secondary hyperparathyroidism.

Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.

Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.

2009

Introduced "Commitment to Life".

2011

Acquired ProStrakan Group plc.

2012

Launch of POTELIGEO® (Mogamulizumab) Injection in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)

2013

Launch of NOURIAST® tablets 20 mg in Japan, a novel antiparkinsonian agent.

2014

ProStrakan Completes Acquisition of Archimedes.

Launch of Sustained-Duration G-CSF Product a® in Japan

2016

Rebranding Western Pharmaceutical Subsidiaries to "Kyowa Kirin"

Launch of LUMICEF® for Psoriasis Treatment in Japan

2018

Crysvita approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia

Poteligeo (mogamulizumab/KW-0761) approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS)

2019

Trade name changed to current "Kyowa Kirin Co., Ltd." from Kyowa Hakko Kirin Co., Ltd.

CI logo of Kyowa Kirin